Cantor Fitzgerald initiated coverage on aTyr Pharma
$ATYR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of aTyr Pharma with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2025 | $16.00 | Outperform | Leerink Partners |
| 1/6/2025 | Overweight | Cantor Fitzgerald | |
| 10/4/2024 | $17.00 | Overweight | Wells Fargo |
| 9/5/2024 | $9.00 | Buy | Jefferies |
4 - aTYR PHARMA INC (0001339970) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)